[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589722":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":42,"centralContacts":46,"locations":52,"responsibleParty":84,"collaborators":86,"id":90,"slug":91,"hasResults":92,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":10,"eligibilityCriteria":96,"healthyVolunteers":92,"sex":97,"minAge":10,"maxAge":10,"enrollmentInfo":98,"targetDuration":10,"studyType":101,"phases":10,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":55,"whyStopped":10,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"Wake Forest University Health Sciences","OTHER",[8,14,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Non-Metastatic and Resectable",null,"Cohort A1: Non-metastatic\u002F Resectable (with planned or you are undergoing therapy)- your cancer has not spread, may be able to remove it with operation",[13],"Other: Non-Metastatic and Resectable",{"label":15,"type":10,"description":16,"interventionNames":17},"Metastatic and Un-resectable","Cohort A2: Metastatic\u002F Unresectable (with planned or you are undergoing therapy)- your cancer has spread, not able to operate at this time to take out all the cancer",[18],"Other: Metastatic and Un-resectable",{"label":20,"type":10,"description":21,"interventionNames":22},"No evidence of disease, under surveillance","Cohort B: No evidence of disease\u002F surveillance (you have completed initial therapy)- currently there is no evidence of your cancer\u002Fdisease and you are under surveillance, meaning your physician is checking your medical situation at intervals or occasionally for any sign of changes",[23],"Other: No evidence of disease, under surveillance",{"label":25,"type":10,"description":26,"interventionNames":27},"ALT or WDLS","Cohort C: You have been diagnosed with ALT (atypical lipoma) or WDLS (well-differentiated liposarcoma)",[28],"Other: ALT or WDLS",[30,33,36,39],{"type":6,"name":9,"description":31,"armGroupLabels":32,"otherNames":10},"Blood Draw Timepoints:\n\n* Before any treatment begins\n* After Neo-adjuvant therapy (only if you receive this type of therapy)\n* After local surgery\n* After Adjuvant therapy (only if you receive this type of therapy)\n* Follow up after adjuvant therapy: at Months 3, 6, 9, 12, 15, 18, and 24\n* After evidence of recurrence or worsening of disease, and then collected at standard of care disease evaluation visits up until 24 months from the last treatment for the initial diagnosis",[9],{"type":6,"name":15,"description":34,"armGroupLabels":35,"otherNames":10},"Blood Draw Timepoints:\n\n* Before any treatment begins\n* During standard of care disease evaluation visits for up to 24 months",[15],{"type":6,"name":20,"description":37,"armGroupLabels":38,"otherNames":10},"Blood Draw Timepoints:\n\n* From completion of treatment- at Months 3, 6, 9, 12, 15, 18, and 24; depending on when you enroll into the study you will start at the next timepoint in this schedule\n* After evidence of recurrence or worsening of disease, and then collected at standard of care disease evaluation visits up until 24 months from the last treatment for the initial diagnosis",[20],{"type":6,"name":25,"description":40,"armGroupLabels":41,"otherNames":10},"Blood Draw Timepoints:\n\n• Collect once after surgery (up to six weeks after surgery)",[25],[43],{"name":44,"affiliation":5,"role":45},"Johann Hsu, MD","PRINCIPAL_INVESTIGATOR",[47],{"name":48,"role":49,"phone":50,"phoneExt":10,"email":51},"Meg Lattanze","CONTACT","980-442-4239","Megan.Lattanze@advocatehealth.org",[53,70],{"facility":54,"status":55,"city":56,"state":57,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"Levine Cancer Institute","RECRUITING","Charlotte","North Carolina","28204","United States","US",{"type":62,"coordinates":63},"Point",[64,65],-80.84313,35.22709,{"lat":65,"lon":64},[68,69],{"name":48,"role":49,"phone":50,"phoneExt":10,"email":51},{"name":44,"role":45,"phone":10,"phoneExt":10,"email":10},{"facility":71,"status":55,"city":72,"state":57,"zip":73,"country":59,"countryCode":60,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Atrium Health Wake Forest Baptist Comprehensive Cancer Center","Winston-Salem","27103",{"type":62,"coordinates":75},[76,77],-80.24422,36.09986,{"lat":77,"lon":76},[80],{"name":81,"role":49,"phone":82,"phoneExt":10,"email":83},"Shailaja Raj","336-716-7970","sraj@wakehealth.edu",{"type":85,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[87],{"name":88,"class":89},"Paula Takacs Foundation","UNKNOWN","100589722","lci-sar-bsts-ctdna-001-circulating-tumor-dna-liquid-biopsy-in-sarcoma-patients-100589722",false,"NCT06958107","LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients","Prospective Clinical Evaluation of Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients","Inclusion Criteria:\n\n1. Written informed consent or assent when applicable from the participant, LAR, parent or legal guardian and HIPAA authorization for release of personal health information.\n2. All ages allowed\n3. Suspected or confirmed disease (must meet one of the criteria below):\n\n   1. Suspected bone or soft tissue tumor concerning for sarcoma (pending confirmation of sarcoma diagnosis)\n\n      OR\n   2. Suspected lipomatous mass concerning for ALT or WDLS with planned surgery\n\n      OR\n   3. Confirmed bone or soft tissue sarcoma meeting one of the criteria below:\n\n      * Non-metastatic\u002FResectable sarcoma with either planned or currently receiving therapy\n      * Metastatic or unresectable sarcoma, with planned or currently receiving therapy\n      * Non-metastatic sarcoma under surveillance with no more than 1 year from completion of therapy\n\nExclusion Criteria:\n\n* none","ALL",{"count":99,"type":100},300,"ESTIMATED","OBSERVATIONAL","The purpose of this research study is to see how well Low Pass Whole Genome Sequencing (LP-WGS) can detect circulating tumor deoxyribonucleic acid (ctDNA) in the blood of participants who have bone or soft tissue sarcoma (type of cancer).",[104],"Sarcoma",[106,107,108],"circulating tumor DNA","liquid biopsy","bone or soft tissue Sarcoma","2026-07-21",{"date":111,"type":112},"2026-07-23","ACTUAL",{"date":114,"type":112},"2025-08-21",{"date":116,"type":100},"2030-01",{"name":5,"class":6},2]